Abstract
AbstractSamples of urine from a patient obtained before and after treatment with 300 mg of the anticancer drug [Pt(II)(NH3)2(CBDCA)] (carboplatin, “Paraplatin”, where CBCDA is 1,1‐dicarboxycyclobutane) have been analysed using 500 MHz 1D and 2D 1H NMR spectroscopy. Peaks for the intact drug and the free ligand CBDCA have been assigned and are present in a mol ratio of ca. 5:1. Only about one half of the total Pt in the sample was present as intact drug. Relative to creatinine and citrate, the excretion of hippurate increased by a factor of ca. 4 after drug treatment. This work suggests that NMR spectroscopy can play a valuable rǒle in studies of carboplatin metabolism.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
